Can Biologics Delay Joint Replacement? A Critical Review of Regenerative Therapies in Knee Osteoarthritis
Made Argyanta Wikananda *
Bhayangkara Denpasar Hospital, Bali, Indonesia.
Agus Eka Wiradiputra
Bhayangkara Denpasar Hospital, Bali, Indonesia.
*Author to whom correspondence should be addressed.
Abstract
Background: Knee osteoarthritis is a leading cause of pain and disability, and total knee arthroplasty remains the definitive treatment for end-stage disease. Biological therapies, including platelet-rich plasma, cell-based preparations, recombinant proteins, monoclonal antibodies and gene-based products, are increasingly offered with the expectation that they might slow disease progression and postpone surgery.
Purpose and scope: This critical narrative review examined whether current evidence supports the claim that biological therapies delay knee arthroplasty in adults with knee osteoarthritis. It considered symptomatic, structural and arthroplasty-related outcomes together, and it treated the timing of arthroplasty as an endpoint whose meaning must itself be appraised.
Approach: Peer-reviewed literature published between January 2005 and September 2026 was identified through biomedical and multidisciplinary scholarly databases, a clinical trial registry, citation tracking and guideline documents. Evidence was appraised qualitatively for design, control of contextual effects, product characterisation, endpoint relevance and follow-up.
Principal Findings: Blood-derived products show modest short- to medium-term symptomatic benefit in several trials, but the largest rigorously blinded trials report no advantage over saline, and structural effects remain unconfirmed. Culture-expanded and minimally manipulated cell preparations produce variable symptomatic gains; recent phase IIb–III trials and a Cochrane synthesis indicate small or uncertain benefits and no demonstrated radiographic disease modification. Among molecular biologics, a recombinant growth factor produced durable but small gains in cartilage thickness without clear symptomatic translation, whereas cytokine blockade largely failed. Anti-nerve growth factor antibodies relieved pain yet increased rapidly progressive osteoarthritis and joint replacement, demonstrating that biological activity can shorten rather than extend time to surgery. Claims that biologics postpone arthroplasty rest almost entirely on uncontrolled or observational data vulnerable to confounding by indication, selection and immortal-time bias.
Unresolved Questions: The optimal product, dose, disease stage and patient phenotype remain undefined, and no adequately powered randomised trial has used time to arthroplasty as a primary endpoint.
Implications and Conclusion: Current evidence does not establish that any biological therapy delays knee arthroplasty. Biological products may offer symptomatic benefit to selected patients, but claims of surgical postponement should be presented as unproven until long-term, placebo-controlled trials with standardised products and validated structural and arthroplasty endpoints are completed.
Keywords: Platelet-rich plasma, mesenchymal stromal cells, disease-modifying osteoarthritis drugs, total knee arthroplasty, orthobiologics, sprifermin, nerve growth factor, time-to-event analysis